Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PharmaDrug (PHRX) has been granted a pre-investigational new drug meeting with the FDA for its COVID-19 treatment
  • The company is studying its patented formulation of cepharanthine, an oral pill for the potential treatment of mild to moderate cases of the virus
  • Cepharanthine has been shown to be highly effective at blocking cell death and viral production following exposure to COVID-19
  • The company anticipates the FDA’s written response to its pre-IND briefing package by late November 2021
  • PharmaDrug researches and develops controlled substances and natural medicines such as psychedelics, cannabis and naturally derived drugs
  • PharmaDrug (PHRX) is up by 11.11 per cent trading at $0.05 per share

PharmaDrug (PHRX) has been granted a pre-investigational new drug meeting with the FDA for its COVID-19 treatment.

The company is studying its patented enteric-coated formulation of cepharanthine (PD-001), an oral pill for the potential treatment of mild to moderate cases of the virus.

Cepharanthine has been shown to be highly effective at blocking cell death and viral production following exposure to COVID-19, but clinical application has been hampered by poor oral bioavailability. PharmaDrug intends to commercialize its oral formulation of cepharanthine to unlock this advantage.  

The pre-IND meeting is meant to develop mutual understanding and agreement between the FDA and the company regarding manufacturing, toxicology, pre-clinical studies, clinical trial design and rationale to support subsequent human clinical trials.

PharmaDrug anticipates the FDA’s written response to its pre-IND briefing package by late November 2021.

Daniel Cohen, Chairman and CEO of PharmaDrug, stated,

“We are pleased to advance our patented, novel formulation of cepharanthine; a potential first-in-class oral antiviral medication for COVID-19. Forthcoming feedback from the FDA will provide us with critical information relevant to defining our parallel development paths for PharmaDrug’s cepharanthine programs in both COVID-19 and rare cancers.”

PharmaDrug researches develops and commercializes controlled substances and natural medicines such as psychedelics, cannabis and naturally-derived drugs.

PharmaDrug (PHRX) is up by 11.11 per cent trading at $0.05 per share as of 9:31 am ET.

More From The Market Herald

" Feel Foods (CSE:FEEL) receives DTC eligibility

Feel Foods (FEEL) has received Depository Trust Company (DTC) eligibility in the United States.

" Andlauer Healthcare Group (TSX:AND) completes $169M bought deal offering

Andlauer Healthcare Group Inc. (AND) and Andlauer Management Group Inc. completed a bought deal offering of 3.5 million subordinate voting shares (SVSs).

" Avricore (TSXV:AVCR) expands HealthTab to select Shoppers Drug Mart locations in BC

Avricore Health (AVCR) has expanded its patient testing with the HealthTab platform in select Shoppers Drug Mart pharmacies in BC.

" Clearmind (CSE:CMND) signs development and supply agreement with Aragen Life Sciences

Clearmind Medicine (CMND) will work with Aragen Life Sciences to produce its innovative molecule, 5-Methoxy-2-aminoindane (MEAI).